Closed Solicitation · DEPT OF DEFENSE
AI Summary
The Department of Defense intends to sole source MERS ELISA kits from AL Genome Medical Company for a seroprevalence study on Middle East Respiratory Syndrome in Jordan. This procurement is conducted under FAR Part 13 Simplified Acquisition Procedures, allowing for a single source due to limited manufacturers. Interested parties may express their capabilities in response to this notice.
This is a notice of intent, not a request for a quotation. A solicitation document will not be issued and quotations will not be requested. This procurement is for MERS ELISA kits. Part of NAMRU EURAFCENT (NAMRU-EAC) achieving its mission is establishing and conducting seroprevalence surveillance study on Middle East Respiratory Syndrome Coronaviruss in Jordan. Since the first outbreak of MERS-CoV that was reported in the Kingdom of Jordan, it has been important to continue monitoring the prevalence of MERS-CoV infections especially at the camel markets and closely monitor the camel traders and handlers to understand the epidemiology and risk factors that might lead to transmission from camels to human. It is also important to determine active cases either symptomatic or asymptomatic with reference to their contact with camels or camel products. Market research showed that not many companies manufacture camel MERS ELISA kits in general so the options were limited. Regarding human MERS IgM ELISA kit, other kits were overviewed as options with RayBiotech’s kit leading as a potential one, but validation of the kit was still being done, so the performance of the kit could not be predicted. That, alongside lower sensitivity and specificity values from other kits manufacturers led to choosing Abbexa kits. AL- Genome Medical Company is the manufacturer and sole vendor for instruments of these kinds of test kits. This acquisition is being conducted using policies unique to the Federal Acquisition Regulation (FAR) Part 13 -Simplified Acquisition Procedures, Subpart 13.106-1(b)(1), For purchases not exceeding the simplified acquisition threshold (SAT), contracting officers may solicit from one source if the contracting officer determines that the circumstance of the contract action deem only one source reasonably available. Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements. Interested parties may identify their interest and capabilities in response to this posting. The determination by the Government not to compete the proposed requirement based upon responses to this notice is solely within the discretion of the Government. Comments to this announcement, referencing this posting number, may be submitted to NAVSUP FLCI, prior to the closing date specified in this announcement, to the attention of Terry Herbert, Contract Specialist via email to by close date.
NOTICE OF INTENT TO SOLE SOURCE- AL GENOME MEDICAL COMPANY is a federal acquisition solicitation issued by DEPT OF DEFENSE. Review the full description, attachments, and submission requirements on SamSearch before the response deadline.
SamSearch Platform
AI-powered intelligence for the right opportunities, the right leads, and the right time.